Shanghai Hongcheng Biopharma at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Shanghai Hongcheng Biopharma brings 4 presentations to ENA 2026 in Barcelona. Its posters span immuno-oncology and antibody-drug conjugates. They include T cell engagers against DLL3 and FcRL5 built with a cis-binding CD58 arm, an anti-CLEC9A ISAC that activates cDC1 cells, and a TAG-72 ADC carrying a pan-RAS(ON) molecular glue payload.

Organization	ENA 2026 Attendance
SH Shanghai Hongcheng Biopharma Shanghai, China
Biotech Biotech developing antibody-drug conjugates, T-cell engagers and immune-stimulating antibody conjugates for cancer.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Development of a Novel TAG-72 Targeting ADC with a proprietary pan-RAS(ON) molecular glue payload ADCs & radioligands Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology A novel biparatopic DLL3 T Cell Engager utilizing a cis-binding CD58 demonstrated superior potency and remarkable safety profile Immuno-oncology Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology Targeted cDC1 Activation via Anti-CLEC9A ISAC Potentiates Anti-Tumor Immunity Immuno-oncology Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology A novel FcRL5-targeting T-cell engager with a cis-binding CD58 costimulatory arm enhances anti-tumor efficacy while mitigating CRS and T-cell fratricide Immuno-oncology

Organization

ENA 2026 Attendance

Shanghai Hongcheng Biopharma

Shanghai, China

Biotech

Biotech developing antibody-drug conjugates, T-cell engagers and immune-stimulating antibody conjugates for cancer.

Poster

Wed Nov 18
12–1:30pm
3:50–4:15pm
5:45–7pm

Part of Poster session: Antibody-drug conjugates

Development of a Novel TAG-72 Targeting ADC with a proprietary pan-RAS(ON) molecular glue payload

ADCs & radioligands

Poster